William Blair initiated coverage on Waters
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
William Blair initiated coverage of Waters with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $440.00 | Buy | Guggenheim |
| 1/5/2026 | Outperform | William Blair | |
| 12/10/2025 | $480.00 | Peer Perform → Outperform | Wolfe Research |
| 12/2/2025 | $423.00 | Equal-Weight | Morgan Stanley |
| 10/8/2025 | $390.00 | Buy | Rothschild & Co Redburn |
| 3/31/2025 | $460.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/26/2025 | $396.00 → $407.00 | Neutral → Outperform | Robert W. Baird |
| 2/13/2025 | $450.00 | Sector Perform → Sector Outperform | Scotiabank |
8-K - WATERS CORP /DE/ (0001000697) (Filer)
425 - WATERS CORP /DE/ (0001000697) (Subject)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders. Immediately following the spin-off, the spun-off entity will be combined with Waters Corporation (NYSE:WAT) ("Waters") in a Reverse Morris Trust transaction. The combination is expected to be completed on February 9, 2026, subject to
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.
MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety o
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.
MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12, 2026, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety o
Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi
MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
4 - WATERS CORP /DE/ (0001000697) (Issuer)
Guggenheim initiated coverage of Waters with a rating of Buy and set a new price target of $440.00
William Blair initiated coverage of Waters with a rating of Outperform
Wolfe Research upgraded Waters from Peer Perform to Outperform and set a new price target of $480.00
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)